# AirNexis gets $200M to test China-derived COPD drug to compete with Merck and GSK

**Source:** Endpoints News
**URL:** https://e.endpointsnews.com/t/t-l-wmlkud-jykykhhuld-h/
**Date:** 2026-01-10

---

Maria Fardis, AirNexis CEO

January 9, 2026 08:00 AM ESTUpdated 08:43 AM FinancingDealsChina

AirNex­is gets $200M to test Chi­na-de­rived COPD drug to com­pete with Mer­ck and GSK

Kyle LaHucik

Biotech Correspondent

An­oth­er biotech has latched on­to the Chi­na-to-US mod­el, putting mon­ey be­hind a Chi­na as­set that will be ad­vanced by an Amer­i­can start­up.

Pa­lo Al­to-based AirNex­is …

---

#news #endpoints-news
